An fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and Its Neural Correlates

Trial Profile

An fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and Its Neural Correlates

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs ABX 1431 (Primary)
  • Indications Central pain; Epilepsy; Neurogenic inflammation; Neurological disorders
  • Focus Therapeutic Use
  • Sponsors Abide Therapeutics
  • Most Recent Events

    • 30 Mar 2018 Status changed from recruiting to completed.
    • 10 May 2017 According to an Abide Therapeutics media release, the company has initiated dosing in this study.
    • 18 Apr 2017 According to an Abide Therapeutics media release, this trial is scheduled to start dosing in the first quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top